secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001730463-26-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus reports preliminary 2025 AUCATZYL rev $75M; guides FY2026 $120-135M
---------------------------------------------------------------------------

- Preliminary unaudited AUCATZYL net product revenue: Q4 2025 ~$24M, full year 2025 ~$75M.
- FY 2026 revenue guidance $120M-$135M; expects positive gross margin in 2026.
- Cash runway extended into Q4 2027 based on current operating plans.
- Pipeline: obe-cel Phase 2 CATULUS (pediatric B-ALL) and LUMINA (lupus nephritis) enrolling; BOBCAT (MS) and AUTO8 (AL amyloidosis) first patients dosed.
- UK commercial launch under NICE approval; manufacturing cost reduction initiatives underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000012/0001730463-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046326000012/autl-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001730463-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer